摘要
急性脑梗死是公认的高致死率、高致残率、高复发率疾病。目前治疗急性脑梗死最有效的方法是溶栓治疗,但溶栓具有出血、神经毒性、过敏等不良反应,影响治疗安全性,给临床应用带来了局限性。该文就国内部分常用的溶栓药物(链激酶、尿激酶、重组组织型纤溶酶原激活剂)以及热点新型溶栓药物(孟替普酶、替奈普酶、去氨普酶、纳豆激酶等)的安全性进行总结,并展望溶栓药物的发展方向。
Acute cerebral infarction is recognized as the disease of high mortality, high morbidity and high recurrence rate. The most effective method to the acute cerebral infarction is thrombolytic therapy. But thrombolysis has side effects of bleeding, neurotoxicity, allergy etc. , which impact the security of the treat- ment,bring limitations to the clinical application. Here is make a summary of the safety of commonly used thrumbolytie drugs, including streptokinase, urokinase, rt-PA, and hot new thrombolytic drugs, including monteplase, desmoteplase, tenecteplase, nattokinase etc. , and a prospect of thrombolytic drugs＇ development.
出处
《医学综述》
2013年第11期2059-2061,共3页
Medical Recapitulate
关键词
溶栓药物
急性脑梗死
溶栓
安全性
Thrombolytic agents
Acute ischemic stroke
Thrombolysis
Safety
